US Supreme Court Temporarily Preserves Mail-Order Access to Abortion Pill Mifepristone
The U.S. Supreme Court issued a temporary order preserving widespread access to mifepristone, rejecting lower-court rulings that sought to ban mail-order distribution and impose in-person visit requirements. This 7-2 emergency decision maintains the status quo for telehealth abortions while legal challenges from Louisiana and anti-abortion groups continue. Justices Thomas and Alito dissented, arguing the ruling undermines previous abortion restrictions. The decision provides immediate relief for patients nationwide but leaves long-term access uncertain as litigation proceeds, highlighting ongoing political and legal tensions surrounding reproductive rights in the post-Roe era.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
SCOTUS Dissent Hints at Next Phase of Abortion Rights Fight via Comstock Act
The US Supreme Court recently ruled that telehealth access to the abortion medication mifepristone can continue, a decision supported by the majority but strongly opposed by Justices Clarence Thomas and Samuel Alito. In their dissenting opinions, the conservative justices characterized the ruling as a scheme to circumvent the 2022 Dobbs v. Jackson decision, which eliminated the federal right to abortion. Justice Thomas specifically argued that the Comstock Act of 1873, an anti-obscenity law prohibiting the mailing of materials for producing abortion, remains valid and should ban the distribution of abortion pills via mail. Although the Department of Justice stated in 2022 that the Act does not prohibit such mailing due to lack of unlawful intent, Thomas and Alito signaled their intent to use this historical statute to challenge abortion access further. Advocates express relief that the immediate threat to mifepristone is mitigated but warn that the dissents indicate a looming legal battle over the Comstock Act, which could potentially disrupt the broader reproductive healthcare supply chain, including surgical tools.
The InterceptSCOTUS Dissent Hints at Next Phase of Abortion Rights Fight via Comstock Act
The US Supreme Court recently ruled that telehealth access to the abortion medication mifepristone can continue, marking a significant development in post-Dobbs reproductive rights litigation. Justices Clarence Thomas and Samuel Alito issued strong dissents, with Alito characterizing the decision as a scheme to circumvent the 2022 Dobbs v. Jackson ruling that eliminated the federal right to abortion. Justice Thomas specifically invoked the Comstock Act of 1873, arguing that this anti-obscenity law prohibits the mailing of drugs used for abortion. Although the Department of Justice has stated that the Comstock Act does not ban such mailings due to lack of unlawful intent, conservative justices appear eager to utilize this dormant statute to challenge abortion access nationally. Advocates express relief that the immediate threat to mifepristone is mitigated but warn that the dissents signal future legal battles. Data indicates that telehealth has become a crucial avenue for abortion care, particularly in states with strict bans, surpassing out-of-state travel in some instances. This ruling highlights the ongoing judicial conflict over reproductive healthcare access and the potential for renewed restrictions through historical laws.
The InterceptSupreme Court Restores Telehealth Access to Abortion Pills Amid Sharp Dissents
The U.S. Supreme Court issued an emergency order on Thursday restoring telehealth access to mifepristone, the primary medication used in abortion procedures. This decision halts a previous ruling by the 5th U.S. Circuit Court of Appeals, which had attempted to prohibit providers from prescribing and mailing the drug across state lines, particularly into states with strict abortion bans. The majority decision allows blue states to continue facilitating access to reproductive healthcare through telemedicine. Justices Clarence Thomas and Samuel Alito filed vigorous dissents. Justice Thomas characterized the distribution network as a criminal enterprise, suggesting providers should face imprisonment under the Comstock Act. Justice Alito expressed frustration that blue states are effectively outmaneuvering the legal framework established by the Dobbs decision, which overturned Roe v. Wade. Alito noted that abortion rates in restrictive states like Louisiana have not decreased due to this cross-state telehealth pipeline. The article highlights the ongoing legal and political conflict surrounding reproductive rights in the post-Dobbs era, emphasizing the strategic responses by pro-choice states to maintain access despite federal and state-level restrictions.
Slate MagazineUS Supreme Court Temporarily Preserves Access to Abortion Pill Mifepristone
The United States Supreme Court has issued a temporary order preserving access to mifepristone, a widely used medication for abortion that is often distributed via mail-order and telehealth services. This decision effectively maintains the status quo by extending a pause on a previous lower court ruling that sought to restrict the drug's availability. The case is currently tied to ongoing legal proceedings involving a lawsuit from Louisiana. While the majority of the court allowed continued access, conservative Justices Clarence Thomas and Samuel Alito filed dissenting opinions. Justice Alito characterized the easy access to abortion pills as a scheme intended to undermine the Court's 2022 decision to overturn Roe v. Wade. In response, Danco Laboratories, the manufacturer of mifepristone, welcomed the ruling, emphasizing the continued availability of a safe and effective drug for Americans. Legal analysts note that this reprieve is temporary, with the Court of Appeals unlikely to rule on the Louisiana suit until after the upcoming November midterm elections. Consequently, the issue may eventually return to the Supreme Court for a final decision on its normal docket, while the FDA continues its own safety review of the medication.
TheWeek feedSupreme Court Blocks Ban on Mailing Abortion Pills in 7-2 Decision
The U.S. Supreme Court has issued a 7-2 decision blocking a lower court ruling that sought to ban the mailing of mifepristone, a key medication used for abortions. This interim ruling allows the drug to remain accessible via telehealth and mail while litigation continues, ending weeks of legal uncertainty following a May 1st decision by the 5th Circuit Court of Appeals that had reinstated nationwide in-person dispensing requirements. The case, Louisiana v. FDA, represents a continued legal battleground over abortion access since the overturning of Roe v. Wade in 2022. Justices Clarence Thomas and Samuel Alito dissented, with Alito arguing the move undermines the Dobbs decision. Advocacy groups praised the ruling as a victory for patient safety and access, citing decades of research supporting the drug's efficacy. However, the legal fight is not concluded, as the Supreme Court has not yet issued a final decision on the merits of the case. The ruling prevents immediate severe restrictions on abortion access in an already constrained legal landscape, maintaining the status quo for now.
Salon.comSupreme Court Temporarily Blocks Ban on Mailing Abortion Pills
The U.S. Supreme Court has issued a 7-2 decision temporarily blocking a lower court ruling that sought to ban the mailing of mifepristone, a key medication used for abortions. This ruling resolves weeks of legal uncertainty following a May 1 decision by the 5th Circuit Court of Appeals, which had reinstated a nationwide in-person dispensing requirement. The Supreme Court's order allows mifepristone to remain accessible via telehealth and mail while litigation continues. Justices Clarence Thomas and Samuel Alito dissented, with Alito arguing the move undermines the Court's previous Dobbs decision. The case stems from ongoing challenges by groups like the Alliance for Hippocratic Medicine and states such as Louisiana, who argue the FDA failed to ensure safety. Advocacy groups, including the Guttmacher Institute and Chicago Abortion Fund, welcomed the decision, emphasizing the drug's proven safety and efficacy. This ruling maintains the status quo for medication abortion access nationwide, though the legal battle is expected to continue as the Court prepares for a final determination on the matter.
Salon.comUS Supreme Court Temporarily Upholds Mail-Order Access to Abortion Pill Mifepristone
The US Supreme Court has temporarily upheld mail-order access to mifepristone, a widely used abortion medication, by extending a stay on a lower court ruling that sought to ban its nationwide delivery by mail. The decision keeps the status quo in place while the Court determines whether to hear the case formally. The underlying lawsuit was initiated by Louisiana, challenging FDA regulations, and had previously led the 5th Circuit Court of Appeals to order a suspension of mail deliveries. Justices Samuel Alito and Clarence Thomas dissented from the Supreme Court's decision to extend the stay. Advocates for reproductive rights, including Nancy Northup of the Center for Reproductive Rights, welcomed the temporary reprieve but warned that it merely buys time without ensuring long-term security, citing concerns over politically motivated reviews by the Trump administration. Mifepristone, approved by the FDA since 2000, is central to medication abortions and miscarriage management. This ruling occurs against a backdrop of heightened restrictions in over 20 states following the 2022 overturning of Roe v. Wade, highlighting the ongoing legal and political conflict surrounding abortion access in the United States.
Digi24Supreme Court Preserves Mifepristone Telemedicine Access via Shadow Docket Stay
The U.S. Supreme Court has issued an order on its shadow docket granting a stay of a Fifth Circuit Court of Appeals decision that sought to block FDA regulations allowing the prescription of mifepristone for abortion via telemedicine. This temporary measure preserves access to the medication while the legal battle continues, with the case expected to return to the Court in the future. The majority opinion did not record individual votes, but Justices Clarence Thomas and Samuel Alito filed dissenting opinions. They argued that the manufacturers failed to demonstrate irreparable harm, noting that federal law (the Comstock Act) technically prohibits mailing abortifacients and that the federal government did not intervene to defend the regulation. The article highlights that the Fifth Circuit's initial blocking order was based on questionable standing and reasoning from previously vacated opinions. Despite the lack of federal government support in this specific filing, the Court sided with the manufacturers, preventing the immediate restriction of telemedicine prescriptions for mifepristone across jurisdictions where it remains legal.
Reason.comSupreme Court Preserves Mail-Order Access to Abortion Pill Mifepristone
The U.S. Supreme Court has issued an emergency order preserving mail-order and pharmacy access to the abortion medication mifepristone, effectively staying a recent Fifth Circuit Court of Appeals ruling that had restricted such access. This decision allows healthcare providers to continue prescribing the drug via telehealth and mail without requiring in-person visits while ongoing litigation proceeds. The stay was granted following an emergency petition by manufacturers Danco Laboratories and GenBioPro, who argued that the lower court's decision created regulatory chaos and hindered time-sensitive medical care. Justices Clarence Thomas and Samuel Alito dissented, with Justice Alito characterizing the move as part of a scheme to undermine the Court's previous overturning of Roe v. Wade. The case originated from a lawsuit by Louisiana Attorney General Liz Murrill against the FDA, challenging policies that expanded access to the drug. Reproductive rights groups, including the ACLU, welcomed the temporary relief, though they noted continued legal challenges. The ruling maintains the status quo for medication abortions, which account for approximately two-thirds of all abortions in the United States, amidst a complex political landscape involving the Trump administration and varying state-level bans.
Healthcare Dive - Latest NewsSupreme Court Preserves Access to Abortion Pill Mifepristone Amid Ongoing Lawsuit
The U.S. Supreme Court has issued an order preserving widespread access to mifepristone, the primary drug used in medication abortions, while legal challenges proceed. The decision rejects lower-court rulings that would have mandated in-person doctor visits and halted mail-order distribution of the drug. This emergency relief allows women to continue obtaining mifepristone via telehealth and pharmacies, maintaining the status quo established by the FDA five years ago. The case stems from a lawsuit by Louisiana, which argues that federal prescribing rules undermine its state abortion ban and questions the drug's safety, despite FDA affirmations. Justices Clarence Thomas and Samuel Alito dissented, criticizing the manufacturers for profiting from what they termed illegal activities under the Comstock Act. The ruling provides temporary stability for abortion access, which accounts for nearly two-thirds of all abortions in the United States. However, advocates warn that the legal battle is not concluded, with potential for further appeals and a full hearing by the high court. The decision highlights ongoing tensions between state-level abortion bans and federal regulatory authority over pharmaceuticals in the post-Roe v. Wade era.
CT MirrorSupreme Court Blocks Lower Court Order Restricting Mifepristone Access
The US Supreme Court has issued an emergency order indefinitely blocking a lower court ruling that sought to restrict access to mifepristone, a commonly used abortion medication. This decision in the case Danco Laboratories v. Louisiana ensures the drug remains available while the justices prepare for full litigation, likely keeping it accessible until at least June 2027. The order was supported by at least five justices, though individual votes were not disclosed as is typical for the Court's shadow docket. Justices Clarence Thomas and Samuel Alito publicly dissented, with Thomas characterizing the pharmaceutical companies as a criminal enterprise under the Comstock Act and Alito suggesting unlawful conspiracy. This marks the second time the Fifth Circuit Court of Appeals has attempted to limit mifepristone access, following a previous unsuccessful attempt dismissed on jurisdictional grounds. The Supreme Court's intervention prevents immediate regulatory uncertainty that would have arisen if the FDA's prescribing rules were struck down without replacement, maintaining the status quo for patients and providers amidst ongoing legal challenges to abortion rights.
VoxSupreme Court Preserves Access to Abortion Pill Mifepristone Amid Ongoing Lawsuit
The U.S. Supreme Court has issued an order preserving widespread access to mifepristone, the most commonly used medication for abortion, while legal challenges continue. The decision rejects lower-court rulings that sought to impose stricter requirements, such as mandatory in-person doctor visits and bans on mail-order delivery. This emergency relief allows women to continue obtaining the drug via telehealth and pharmacies, ensuring uninterrupted access likely until at least next year. The case stems from a lawsuit by Louisiana, which argues that federal FDA regulations undermine state abortion bans and question the drug's safety, despite long-standing FDA approvals. Justices Clarence Thomas and Samuel Alito dissented, criticizing the manufacturers for profiting from what they termed illegal activities under the Comstock Act. The ruling occurs against a backdrop of political tension, with anti-abortion groups pressuring the Trump administration to restrict the drug further, leading to the recent resignation of FDA Commissioner Marty Makary. Medical groups and pharmaceutical companies have supported maintaining current access levels, warning that restrictions could disrupt the broader drug approval process.
WBUR NewsSupreme Court Preserves Access to Abortion Pill Mifepristone Amid Ongoing Lawsuit
The U.S. Supreme Court has issued an order preserving widespread access to mifepristone, the drug used in the majority of abortions in the United States. The decision rejects lower-court rulings that sought to impose stricter regulations, such as requiring in-person doctor visits and banning mail-order distribution, while legal challenges continue. This emergency relief allows women to obtain the medication via telehealth and mail without interruption, likely until at least next year. The case stems from a lawsuit by Louisiana, which argues that federal FDA rules undermine state abortion bans and question the drug's safety, despite long-standing FDA approvals. Justices Clarence Thomas and Samuel Alito dissented, criticizing the manufacturers for profiting from what they termed illegal activities under the Comstock Act. The ruling occurs against a backdrop of political tension, with anti-abortion groups pressuring the Trump administration to restrict the drug further, leading to the recent resignation of FDA Commissioner Marty Makary. Medical groups and pharmaceutical industries have supported maintaining current access levels, warning that restrictions could disrupt the broader drug approval process.
WBUR NewsSupreme Court Keeps Mifepristone Available Pending Further Review
The U.S. Supreme Court issued an unsigned order maintaining the availability of mifepristone, effectively blocking a Fifth Circuit Court of Appeals ruling that sought to reimpose in-person dispensing requirements and ban mail-order distribution of the abortion pill. The decision provides a temporary reprieve for patients and providers while the case proceeds to be heard on its merits. Justices Samuel Alito and Clarence Thomas filed separate dissents. Justice Thomas argued that the manufacturers are not entitled to relief under the Comstock Act, characterizing their business as criminal. Justice Alito expressed strong opposition, criticizing the majority for undermining the Dobbs decision and attacking the drug manufacturers, Danco and GenBioPro, for profiting from what he termed felonious use. He also voiced frustration with the FDA's neutral stance. The article notes that this legal battle represents a primary focus for the anti-abortion movement following the overturning of Roe v. Wade, with future restrictions depending on the Court's final ruling and potential changes in FDA leadership under the Trump administration.
TPM – Talking Points MemoSupreme Court Allows Mailing of Abortion Pills to Continue Amid Louisiana Challenge
The U.S. Supreme Court has issued a decision allowing the mailing of mifepristone, a key medication used in abortions, to continue via telehealth services. This ruling blocks a previous decision by the 5th U.S. Circuit Court of Appeals that had briefly enforced a national ban on mailing the drug. The case stems from a legal challenge filed by Louisiana Attorney General Liz Murrill, who argued that the FDA insufficiently considered safety risks when approving remote distribution. Despite the temporary reprieve, the legal battle persists as Louisiana continues to contest the drug's legality, with the possibility of future Supreme Court arguments. Medical providers have welcomed the decision but expressed concern over the confusion caused by fluctuating legal statuses. Data indicates that telehealth abortions now comprise approximately 25% of all procedures, serving many patients in states with strict abortion bans. Conservative Justices Clarence Thomas and Samuel Alito dissented, with Thomas citing the Comstock Act as grounds for prohibiting the mail distribution of abortion medications.
The 19th